FDA Advisers Back Eli Lilly’s Groundbreaking Alzheimer’s Drug
Eli Lilly’s new Alzheimer's drug, donanemab, received unanimous backing from FDA advisers on June 10, 2024.
Read moreEli Lilly’s new Alzheimer's drug, donanemab, received unanimous backing from FDA advisers on June 10, 2024.
Read more© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Disclaimer.
© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Disclaimer.